



Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/666,430
		Filing Date	September 21, 2000
		First Named Inventor	Rea et al.
		Group Art Unit	1644
		Examiner Name	G. Ewald VanderVegt
		Attorney Docket Number	3157-4205 IUS
Sheet	1	of	1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/PV/		Abul K. Abbas, M.B.B.S. <i>et al.</i> , Cellular and Molecular Immunology, Antigen Presentation and T Cell Antigen Recognition, pp. 115-37, W. B. Saunders Co., Philadelphia, Pennsylvania, 1991.	
		AHFS Drug Information 91 pp. 1810, American Society of Hospital Pharmacists, Inc., Bethesda, Maryland, 1991.	
		Arthur J. Vander, M.D. <i>et al.</i> , Human Physiology: The Mechanisms of Body Function, Defense Mechanisms of the Body: Immunology, Foreign Chemicals and Stress, pp. 599-640, Mary Jane Martin and Susan Hazlett eds., McGraw-Hill Book Co. 4th ed. New York, New York, 1985.	
		Bruce Alberts <i>et al.</i> , Molecular Biology of The Cell, The Immune System, 2nd ed. Garland Publishing, Inc., New York, New York, 1989, pp. 1044-1048.	
		King <i>et al.</i> , Dictionary of Genetics, Fifth Edition, pp. 14, 332, Oxford University Press, New York, New York, 1997.	
		Goodman <i>et al.</i> , Goodman and Gilman's The Pharmacological Basis of Therapeutics, (Seventh Ed.) Ch 63 Adrenocorticotrophic Hormone: Adrenocortical Steroids and their Synthetic Analogs: Inhibitors of Adrenocortical Steroid Biosynthesis, pp. 1459-1489, MacMillan Publishing Company, New York, New York, 1985.	
↓		Remington's Pharmaceutical Sciences, Lypressin, pp. 958-72, Mack Publishing Company, Easton, Pennsylvania, Alfonso R. Gennaro ed., 1985.	

Examiner Signature	/F Pierre Vandervegt/	Date Considered	09/26/2007
-----------------------	-----------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.